Drug Profile
Tozinameran - BioNTech/Pfizer
Alternative Names: BNT 162; BNT 162b2; Bnt-162b2; BNT162b2 vaccine; BNT162b2SA; COMIRNATY; COVID-19 Vaccine, mRNA - BioNTech/Pfizer; PF-07302048; Pfizer-BioNTech COVID-19 vaccine; Pfizer-BioNTech vaccine; SARS-CoV-2 RNA vaccine - BioNTech/PfizerLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator BioNTech; University of Roma La Sapienza
- Developer BioNTech; Pfizer; Pfizer Japan; Shanghai Fosun Pharmaceutical
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed COVID 2019 infections
- Phase II SARS-CoV-2 acute respiratory disease
Most Recent Events
- 18 Mar 2024 BioNTech withdraws a phase I trial in COVID-19 (In Children, In Infants, Prevention) prior to enrollment (IM, Injection) (NCT05630352)
- 07 Mar 2024 Launched for COVID-2019 infections (Prevention) in Germany (IM) (Prior to March 2024)
- 07 Mar 2024 Launched for COVID-2019 infections (Prevention) in Turkey (Parenteral) (Prior to March 2024)